JAMP-METHOTREXATE SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

METHOTREXATE (METHOTREXATE SODIUM)

Pieejams no:

JAMP PHARMA CORPORATION

ATĶ kods:

L01BA01

SNN (starptautisko nepatentēto nosaukumu):

METHOTREXATE

Deva:

25MG

Zāļu forma:

SOLUTION

Kompozīcija:

METHOTREXATE (METHOTREXATE SODIUM) 25MG

Ievadīšanas:

INTRA-ARTERIAL

Vienības iepakojumā:

2ML/40ML

Receptes veids:

Prescription

Ārstniecības joma:

ANTINEOPLASTIC AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0107545002; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2022-11-14

Produkta apraksts

JAMP-METHOTREXATE, METHOTREXATE INJECTION USP, 25 MG/ML UNPRESERVED
PAGE 1 OF 69
PRODUCT MONOGRAPH
Pr
Jamp-METHOTREXATE
Methotrexate Injection USP
Unpreserved
Methotrexate 25 mg/mL
Sterile Solution
ANTIMETABOLITE AND ANTIRHEUMATIC JAMP PHARMA CORPORATION DATE OF REVISION
:
September 25, 2019
1310 rue Nobel
Boucherville, Québec
Canada J4B 5H3
SUBMISSION CONTROL NO.:
230627
JAMP-METHOTREXATE, METHOTREXATE INJECTION USP, 25 MG/ML UNPRESERVED
PAGE 2 OF 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
5
ADVERSE REACTIONS
..........................................................................................................
12
DRUG INTERACTIONS
..........................................................................................................
15
DOSAGE AND ADMINISTRATION
.....................................................................................
19
OVERDOSAGE
......................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 28
STORAGE AND
STABILITY..................................................................................................
30
SPECIAL HANDLING INSTRUCTIONS
.............................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 32
PART II: SCIENTIFIC INFORMATION
.......................................